Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus by Anna Czarnota et al.




hepatitis B small surface antigen particles 
exposing highly conserved E2 epitope 
of hepatitis C virus
Anna Czarnota1, Jolanta Tyborowska2, Grażyna Peszyńska‑Sularz3, Beata Gromadzka2, 
Krystyna Bieńkowska‑Szewczyk1 and Katarzyna Grzyb1*
Abstract 
Background: Hepatitis C virus (HCV) infection is a major health problem worldwide, affecting an estimated 2–3 % of 
human population. An HCV vaccine, however, remains unavailable. High viral diversity poses a challenge in developing a 
vaccine capable of eliciting a broad neutralizing antibody response against all HCV genotypes. The small surface antigen 
(sHBsAg) of hepatitis B virus (HBV) has the ability to form highly immunogenic subviral particles which are currently used 
as an efficient anti‑HBV vaccine. It also represents an attractive antigen carrier for the delivery of foreign sequences. In 
the present study, we propose a bivalent vaccine candidate based on novel chimeric particles in which highly conserved 
epitope of HCV E2 glycoprotein (residues 412–425) was inserted into the hydrophilic loop of sHBsAg.
Results: The expression of chimeric protein was performed in an unconventional, Leishmania tarentolae expression sys‑
tem resulting in an assembly of particles which retained immunogenicity of both HCV epitope and sHBsAg protein. Direct 
transmission electron microscopy observation and immunogold staining confirmed the formation of spherical particles 
approximately 22 nm in diameter, and proper foreign epitope exposition. Furthermore, the sera of mice immunized with 
chimeric particles proved reactive not only to purified yeast‑derived sHBsAg proteins but also HCV E2 412–425 synthetic 
peptide. Most importantly, they were also able to cross‑react with E1E2 complexes from different HCV genotypes.
Conclusions: For the first time, we confirmed successful assembly of chimeric sHBsAg virus‑like particles (VLPs) in 
the L. tarentolae expression system which has the potential to produce high‑yields of properly N‑glycosylated mam‑
malian proteins. We also proved that chimeric Leishmania‑derived VLPs are highly immunogenic and able to elicit 
cross‑reactive antibody response against HCV. This approach may prove useful in the development of a bivalent pro‑
phylactic vaccine against HBV and HCV and opens up a new and low‑cost opportunity for the production of chimeric 
sHBsAg VLPs requiring N‑glycosylation process for their proper functionality and immunogenicity.
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Background
Although recent advances in hepatitis C treatment give 
reasons for optimism, a prophylactic vaccine for hepati-
tis C virus (HCV) remains an elusive goal. The recently 
developed direct-acting antiviral drugs (DAAs) have 
improved the sustained viral response (SVR) rates up to 
even 99 % for Sofosbuvir/Ledipasvir therapy [1]. Unfortu-
nately, the cost of the DAA therapy is still extremely high 
[2]. Considering the above, the development of an effec-
tive prophylactic vaccine against HCV should be a medi-
cal priority. HCV infection affects an estimated 2–3  % 
of human population and the number is even higher in 
undeveloped countries, including Egypt with the HCV 
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prevalence of 20  % [3]. Approximately 70–80  % of the 
infected individuals develop chronic liver disease, which 
can lead to cirrhosis and liver carcinoma.
HCV is a member of the Flaviviridae family. Its sin-
gle stranded positive-sense RNA genome codes for both 
structural and non-structural viral proteins. The HCV 
nucleocapsid is surrounded by E1E2 envelope glycopro-
teins embedded in a lipid envelope. E1 and E2 glycopro-
teins constitute a potential target for the development of a 
prophylactic HCV vaccine, as they are involved in virus–
host interaction, and the antibodies directed against these 
proteins seem to neutralize HCV [4]. Due to the fact that 
resolution of HCV infection is mediated not only by a 
broad and potent T cell response [5], but also by the neu-
tralizing antibodies (nAbs) raised mainly against HCV 
E1E2 heterodimer [6, 7], a prophylactic vaccine consist-
ing of adjuvanted recombinant E1E2 heterodimer was 
proposed. The most advanced approach included immu-
nization with E1E2 complex expressed in Chinese ham-
ster ovary (CHO) cell line. Phase I clinical trials indicated 
that immunization with glycosylated envelope proteins 
resulted in potent nAbs and CD 4+ T-cell responses [8, 9].
The major obstacle in the development of a protective 
immunity against HCV is its high genetic diversity and 
variability. In recent studies, HBV capsid-like particles 
(CLPs) were used to present variants of the HCV E2 gly-
coprotein hyper-variable region 1 (HVR1). HVR1 is one 
of the most immunogenic regions of glycoprotein E2, but 
its constant evolution and diversity along HCV genotypes 
leads to limited cross-reactivity of the elicited antibodies 
[10]. The region located downstream of HVR1 contains a 
potent and highly conserved epitope first identified by the 
mouse monoclonal antibody AP33. The region, spanning 
residues 412–423 of glycoprotein E2, can elicit broadly 
nAbs capable of inhibiting HCV, both in vitro and in vivo 
[11, 12]. Epitope AP33 is highly conserved among over 
5500 E2 sequences in the GenBank database and mostly 
regarded as a linear epitope [11]. These features make 
412–423 residues a perfect peptide antigen expressed 
on various antigen carriers. Moreover, the region is only 
13 amino acids long and does not include any additional 
cysteine residue that could result in formation of non-
authentic disulfide bonds and disrupt the carrier struc-
ture [13]. In general, peptide vaccines used in isolation are 
weakly immunogenic and require some carries for deliv-
ery [14]. This finds support in a recently published report 
which shows that monoclonal antibodies (mAbs) gen-
erated against a cyclic variant of the AP33 epitope bind 
poorly to E2 and do not neutralize the virus [15].
Yeast-derived HBV small surface antigen (sHBsAg) 
forms particles 22 nm in diameter currently used world-
wide as the commercial recombinant hepatitis B vac-
cine. sHBsAg tertiary structure forms a highly conserved, 
hydrophilic loop containing the major B-cell epitopes 
also known as the “a”-determinant [16, 17]. Because of its 
immunogenic potential, sHBsAg was also applied as an 
antigen carrier to deliver foreign sequences and induce 
anti-foreign humoral and cellular responses [13, 18–25].
The present study focused on construction, characteri-
zation and immunological studies of novel sHBsAg chi-
meric particles produced in the L. tarentolae expression 
system. The system enables production of recombinant 
proteins with their mammalian-like N-glycosylation pat-
tern. Moreover, L. tarentolae can grow in biofermenters to 
a high cell density and the recombinant protein produc-
tion yield can reach several milligrams per liter of culture 
[26, 27]. Here, we propose a new vaccine candidate based 
on chimeric particles in which the HCV E2 glycoprotein 
region (aa 412–425) is inserted within the “a”-determi-
nant loop of sHBsAg. We show that Leishmania-derived 
HBV/HCV chimeric particles elicit promising titers of 
cross-reactive antibodies against HCV. These particles 
also induce both humoral and cellular immune response 
against HBV, opening a new and low-cost approach to 
bivalent vaccine development.
Results
Expression and characterization of sHBsAg and 412–425_
sHBsAg particles
The HCV E2 glycoprotein region spanning 412–425 
residues was chosen as the epitope of broadly neutraliz-
ing properties [28] and inserted into the major antigenic 
loop of HBV sHBsAg protein (Fig.  1). The expression 
of the recombinant proteins was carried out in high-
density cell cultures of recombinant parasites, using 
tetracycline-inducible L. tarentolae expression system. 
The expression of proteins was confirmed by immuno-
fluorescence (Fig. 2a), western blot (Fig. 2b) and ELISA 
(Fig.  2c) with protein-specific antibodies: anti-HBsAg 
and anti-E2 (AP33). The confocal studies indicate that 
both proteins are predominantly located in the cytosol 
of L. tarentolae cells, probably in endoplasmic reticu-
lum (ER). No particle secretion into the culture medium 
was observed. The western blot analysis of cell lysates 
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Fig. 1 Schematic illustration of the sHBsAg sequence with the 
foreign HCV E2 412–425 epitope inserted into the “a”‑determinant 
region. The sHBsAg insertion site corresponding to amino acid posi‑
tions 127 and 128 is marked red. The numbering corresponds to the 
amino acid positions in the sHBsAg protein. The 412–425 epitope of 
the HCV E2 glycoprotein is shown in green
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showed that in reducing conditions, the molecular 
masses of monomers of sHBsAg and 412–425_sHB-
sAg were approximately 27 and 30  kDa, respectively 
(Fig. 2b). The difference in the molecular masses of the 
monomers is probably associated not only with the 
insertion of the 14 aa long fragment but also with the 
molecular mass of the N-glycans. The chimeric pro-
tein 412–425_sHBsAg contains two additional N-gly-
cosylation sites at positions 417 and 423 versus the 
wild-type sHBsAg. N-glycosylation of 412–425_sHB-
sAg was confirmed by reaction with PNGase F, where 
a decrease in the protein molecular weight after endo-
glycosidase digestion was observed (Fig.  2b). In ELISA 
test, 412–425_sHBsAg chimeric particles were specifi-
cally and efficiently recognized by neutralizing AP33 
mAb with no cross-reactivity with sHBsAg particles. 
412–425_sHBsAg particles were also recognized by pol-
yclonal anti-HBsAg antibodies at the efficacy similar to 
that of sHBsAg (Fig. 2c).
The sHBsAg and 412–425_sHBsAg particles were 
partially purified from cell lysate by ultracentrifugation 
on OptiPrep gradient, and 0.5  mL fractions were har-
vested and analyzed by western blot using anti-HBsAg 
antibodies. The purity of the fractions was estimated 
with Coomassie stained SDS-PAGE gel (Fig. 3). Multim-
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Fig. 2 Characterization of the particles expressed in the L. tarentolae system. a Immunofluorescence of recombinant L. tarentolae cells transfected 
with plasmids expressing 412–425_sHBsAg and sHBsAg. Cells transfected with empty pLEXSY_I‑blecherry3 plasmid were used as negative control 
(NC). The staining was carried out using AP33 mAbs (blue) and anti‑HBsAg Abs (green), scale bar = 5 µm. b Western blot analysis of the Leishmania‑
derived particles in reducing conditions. sHBsAg and 412–425_sHBsAg were treated with PNGase F and detected using the anti‑HBsAg specific 
antibody. G represents the glycosylated and DG deglycosylated form of protein. c Recognition of particles with anti‑HBsAg and AP33 Abs in the 
ELISA tests. ELISA plates were coated with serial dilutions of recombinant L. tarentolae cell lysates containing sHBsAg and 412–425_sHBsAg particles. 
The dilution factor is depicted on x‑axis. For each ELISA assay, the mean from three independent experiments performed in duplicate is shown. The 
mean A450 values and standard deviations are shown on the y‑axis. The background from the L. tarentolae wild‑type cell lysate in each dilution was 
subtracted from the obtained results
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proteins. Fractions with the highest concentration of par-
ticles were pooled, and protein concentration measured 
by Bradford assay reached 15–20 mg/L of the induced cell 
culture. Interestingly, one-step purification process of the 
particles on OptiPrep gradient proved effective. Finally, 
electron microscopy analysis of the 412–425_sHBsAg 
fraction showed spherical-particles approximately 22 nm 
in diameter, with morphology resembling the icosahedral 
structures of P. pastoris-derived particles [29]. Addition-
ally, immunogold labeling of 412–425_sHBsAg particles 
with AP33 antibodies specific to the 412–425 epitope 
revealed selective labeling of 22  nm particles, which 
suggests strongly that the 412–425 epitope is properly 
exposed on the surface of sHBsAg particles (Fig.  4). In 
summary, these results confirm an efficient expression of 
both sHBsAg and 412–425_sHBsAg proteins as well as 
a proper exposition of the 412–425 epitope on sHBsAg 
carrier.
Immunogenicity of sHBsAg and 412–425_sHBsAg particles
To demonstrate immunogenicity of sHBsAg and chi-
meric 412–425_sHBsAg particles, two groups of BALB/c 
mice were immunized subcutaneously on days: 0, 14, and 
28 with fractions containing sHBsAg or 412–425_sHB-
sAg particles. All mice were immunized in presence of a 
squalene-based oil-in-water nanoemulsion adjuvant. Two 
weeks after the last vaccination, splenocytes were isolated 
and T cell response was analyzed by gamma interferon 
(IFN-γ) enzyme-linked immune spot (ELISPOT) assay. 
For splenocytes stimulation we designed peptides cover-
ing the entire sHBsAg protein sequence, 15 amino acids 
in length with an overlap of 10. The peptides were divided 
into three pools corresponding to amino acid positions: 
1–99 (P1 n = 19), 100–188 (P2 n = 16) and 189–240 (P3 
n = 9). IFN-γ ELISPOT data were found comparable for 
both antigens, however a more potent cellular response 
was noted for 412–425_sHBsAg. The strongest T-cell 
response was observed for pools 1 and 3 (Fig. 5).
Two weeks after the last immunization blood samples 
were collected and the antibody titers determined. Pooled 
sera reacted strongly to the antigens used for immuniza-
tion, with the endpoint titer reaching as high as 5 × 105 







Fig. 3 OptiPrep density gradient centrifugation of recombinant 
particles. Seventeen fractions of 0.5 mL each were harvested from the 
top of the OptiPrep gradient after centrifugation. The aliquots of each 
fraction were analyzed by SDS‑PAGE Coomassie blue staining (CB) 
and western‑blot (WB) with anti‑HBsAg Abs. The figure represents the 
results of fractions 8–10 where the highest amount of particles was 
detected
Fig. 4 Electron micrograph of chimeric 412–425_sHBsAg parti‑
cles. After centrifugation on OptiPrep gradient, the particles were 
negatively stained with uranyl acetate and analyzed by electron 
microscopy (top). Numerous particles approximately 22 nm in 
diameter were observed. The exposition of the 412–425 epitope was 
studied by immunogold labeling using AP33 mAbs and secondary 
goat anti‑mouse Abs conjugated with 6 nm gold particles (bottom). 
Scale bar 100 nm
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412–425_sHBsAg particles when detected with sera from 
sHBsAg immunized mice (Fig. 6a right). Detailed serum 
characterization showed cross-reactivity with both puri-
fied yeast-derived HBsAg protein (yHBsAg) and a com-
mercially available HBV vaccine (Engerix-B) (Fig.  6b). 
The results proved that sera from both groups of mice 
contained high titers of anti-sHBsAg antibodies, and 
this suggests that 14 aa foreign epitope insertion within 
sHBsAg particle does not interfere dramatically with the 
humoral response against sHBsAg protein itself. Simi-
lar induction of anti-HBsAg antibodies was observed in 
mice immunized with chimeric HBsAg particles which 
delivered HCV-specific cysteine-containing sequence 
[13]. However, the immune response against sHBsAg 
protein was lower in the 412–425_sHBsAg group of mice 
compared to the sHBsAg wild-type group. Of note, the 
absorbance values obtained for the purified yHBsAg pro-
tein were higher than those obtained from the vaccine 
(Fig. 6b). This can be caused by the fact that sHBsAg par-
ticles in vaccines are associated to aluminium hydroxide 
which can lower test sensitivity due to epitope coverage 
[30].
Next, we studied the antibody response of 412–425_
sHBsAg particles to 412–425 epitope. Interestingly, sera 
from the 412–425_sHBsAg group were able to recognize 
not only the sHBsAg protein (as mentioned above), but 
also synthetic peptide corresponding to the 412–425 
region of HCV E2 glycoprotein. The endpoint titer in 
peptide ELISA test reached 103. The AP33 standard 
curve showed that the amount of anti-412–425 epitope 
antibody in serum corresponded to AP33 antibody con-
centration of approximately 0.9  mg/mL (Fig.  6c). Fur-
thermore, we decided to test cross-reactivity of the sera 
from 412–425_sHBsAg immunized mice against E1E2 
complex from different HCV genotypes. As expected, the 
antisera recognized E2 glycoproteins from HCV geno-
types 1a, 1b, 2b, 3a, 4, and 6, but failed to recognize E2 
derived from genotype five (Fig. 6d). That was due to the 
fact that genotype five isolate had 4 amino acid changes 
in region 412–423 in comparison with the sequence used 
to create 412–425_sHBsAg protein. Such a modification 
may influence epitope recognition as well as neutraliza-
tion of the HCV pseudotype particles (HCVpp) [11]. All 
facts considered, the 412–425_sHBsAg sera were found 
broadly cross-reactive across the HCV genotypes.
To recapitulate, the immunization studies confirmed 
that both Leishmania-derived particles are highly immu-
nogenic in mice. Moreover, the 412–425_sHBsAg sera 
recognized efficiently both the 412–425 peptide and 
mammalian cell culture-derived E2 protein from dif-
ferent HCV genotypes, as well as yeast-derived sHBsAg 
proteins.
Discussion
Despite the discovery of highly effective antiviral agents, 
3–4 million new HCV infections every year still represent 
a major health problem. Therefore, the development of 
an effective and a low-cost prophylactic vaccine is needed 
to control global HCV infection. For years, humoral 
response and nAbs were considered to play a side role in 
HCV infection process. However, recent studies suggest 
that nAbs play an active role in HCV spontaneous res-
olution [6, 7, 31]. During the infection, all known nAbs 
target epitopes within the HCV envelope glycoproteins 
E1 and E2, prevailingly the E2 epitopes. The ectodomain 
of the E2 glycoprotein contains three regions of vari-
ability that are targeted by nAbs—HVR1, HVR2, plus the 


































Fig. 5 Analysis of cellular response in BALB/c mice immunized with Leishmania‑derived particles. Box plot of antigen‑specific IFN‑γ ELISPOT 
responses in sHBsAg (right) and 412–425_sHBsAg (left) groups of immunized mice. Splenocytes from six immunized BALB/c mice per group were 
stimulated with 20 µg/well of 43 different 15‑mer overlapping peptides spanning the sHBsAg protein sequence pooled into three groups (P1, P2, 
P3). The splenocytes were collected 2 weeks after the last immunization. The gray region is the 25–75th percentile; the horizontal lines indicate the 
mean (dashed) and median (solid) values
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Fig. 6 Analysis of the humoral response induced by Leishmania‑derived particles in BALB/c mice. a Analysis of the antibody endpoint titers of the 
pooled mouse antisera specific to the recombinant particles. ELISA plates were coated with 412–425_sHBsAg (right) or sHBsAg (left) particles. b 
Analysis of the interaction of immune sera with yeast‑derived HBsAg proteins. ELISA plates were coated with 5 µg/mL of purified HBsAg protein 
from P. pastoris (yHBsAg) (right) or commercially available vaccine against HBV (Engerix‑B) (left). c Analysis of the antibody response to the 412–425 
synthetic peptide. ELISA plates were coated with 20 µg of 412–425 peptide. AP33 mAb was used to estimate concentration of Abs specific to the 
412–425 region in serum. Dilution factor of the pooled 412–425_sHBsAg sera and concentration of the AP33 antibody are shown on x‑axis (bottom 
and top, respectively). The 412–425_sHBsAg sera values are represented with bars, the AP33 values are marked with solid line. Mean A450 values and 
standard deviations are shown on the y‑axis. The background from the negative control serum in each dilution was subtracted from the obtained 
results (a, b, c). For each ELISA assay, the mean from three independent experiments performed in duplicate is shown. Asterisks indicate statistical 
significance (*P < 0.05, paired two‑tailed t‑test) (a, b). The solid horizontal line (a, b) indicates the cutoff value (three times the mean background 
value). d Analysis of cross‑reactivity of the 412–425_sHBsAg sera to the E1E2 complex from different HCV genotypes. The figure represents western 
blotting in reducing conditions with 412–425_sHBsAg sera diluted 1:500. As an antigen, extracts of HEK293 cells transfected with plasmids express‑
ing E1E2 glycoproteins from different HCV genotypes were used. Non‑transfected HEK293 cell lysate was used as negative control (NC)
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fragment responsible for interactions with cellular SR-BI 
receptor [32]. Because of its high immunogenicity, HVR1 
was often considered a potential vaccine epitope. How-
ever, a recent approach where HVR1 is used as an antigen 
carried on HBV capsid-like particles showed deficiency 
in the HCVpp and cell culture HCV (HCVcc) cross-neu-
tralization [10]. Unfortunately, HVR1 is the most variable 
region of HCV and the high rate of mutation within this 
region results in poor cross-neutralization across differ-
ent HCV isolates. It has been reported that HVR1 plays 
the role of a major epitope decoy that elicits isolate-spe-
cific nAbs from which the HCV can easily escape [33].
It has previously been demonstrated that CD81-bind-
ing regions of HCV E2 glycoprotein are highly conserved 
and represent the main target for the broad range of nAbs 
[11, 31, 34, 35]. Thus, the intrinsically conserved epitopes 
able to induce cross-neutralizing antibodies seem to be 
essential in vaccine development. The recent data suggest 
that recombinant E1E2 complex is capable of eliciting 
antibodies that bind the conserved residues overlapping 
epitopes of many broadly cross-neutralizing antibodies 
targeting E2-CD81 interaction [36].
In this study, we decided to design particles carry-
ing broadly-neutralizing 412–425 epitope and insert it 
into the major antigenic loop of sHBsAg protein. Both 
sHBsAg (wild-type) and 412–425_sHBsAg (chimeric) 
proteins were expressed in L. tarentolae cells at similar 
efficiencies. The fact indicates that epitope insertion did 
not impair the protein folding. This is consistent with 
observation from previous study which showed that 
“a”-determinant of sHBsAg can support 36 amino acids 
insertions without an impact on the particle expression 
efficiency [23]. The insertion of 412–425 epitope in “a”-
determinant was confirmed by cell lysate ELISA and 
immunogold labeling of particles with AP33 antibodies. 
The EM analysis revealed that 412–425_sHBsAg particles 
were present in the cell lysate and their shape resembled 
the correctly assembled sHBsAg particles expressed in 
the mammalian or yeast expression systems [29, 37].
Over the last few years, new vaccination approaches 
involving VLP-based vaccines have been developed. VLP 
are effective immunogens and due to their highly organ-
ized structure they are able to elicit both the nAbs and 
T-cell responses [38]. sHBsAg has been shown to self-
assemble into highly immunogenic, non-infectious subvi-
ral particles, and is used worldwide as a safe, commercial 
hepatitis B vaccine. The sHBsAg protein was previously 
expressed in mammalian [37], baculovirus [39], E.coli 
[40], and yeast systems utilizing P. pastoris [29, 41], S. 
cerevisiae [42], H. polymorpha [37], and Y. lipolytica [43]. 
The choice of S. cerevisiae yeast for commercial produc-
tion of sHBsAg was dictated by low cultivation costs and 
high protein yield. However, unlike in the mammalian 
expression system, the yeast-derived sHBsAg is not gly-
cosylated, which is a major drawback of the yeast-based 
systems. Noteworthy, sHBsAg expression in mammalian 
cells leads to particle secretion [18, 23, 44]. The process 
significantly simplifies purification of particles from the 
culture medium. On the other hand, particle secretion 
was never observed in yeast systems where protein was 
retained within ER partially assembling into multi-layer 
lamellar structures. There is no evidence for the pres-
ence of the particles within the yeast cells [29]. Impor-
tantly, the assembly of L. tarentolae expressed particles 
was confirmed by electron microscopy, though we never 
observed any particle secretion into the culture medium. 
They are possibly retained in ER, just as the yeast-derived 
virus-like particles (VLPs), and the assembly of the parti-
cles probably occurs after the cell lysis in the subsequent 
down-stream processing.
This report is the first to describe efficient expression 
of sHBsAg in a eukaryotic protozoan L. tarentolae-based 
expression system. The L. tarentolae system has recently 
been used to express immunogenic human papilloma-
virus (HPV) L1 VLPs [45] and to produce recombinant 
proteins with the N-glycosylation pattern similar to the 
mammalian one, as demonstrated for erythropoietin [26] 
and soluble amyloid precursor protein alpha (sAPPal-
pha) [46]. Region 412–425 of the HCV E2 glycoprotein 
includes two highly conserved glycosylation sites which 
have recently been shown to play an important role in 
epitope recognition by the broadly neutralizing mono-
clonal antibodies AP33, HCV1 [47], and HC33.11 [48]. 
Moreover, it has previously been shown that the struc-
ture of oligosaccharides attached to hemagglutinin can 
play an important role in its immunogenicity [49]. The 
N-glycosylation pattern of L. tarentolae-derived particles 
should be further analyzed, although higher mass of the 
412–425_sHBsAg protein and the results of deglycosyla-
tion with PNGase F suggest the presence of additional 
N-glycans.
Recently, various strategies of using sHBsAg as the pro-
phylactic HCV vaccine candidates have been investigated. 
It has been shown that pre-existing immunity to sHB-
sAg does not impede immune response against foreign 
epitopes or proteins carried on an sHBsAg particle. This 
suggests that chimeric HBsAg-based particles can be used 
in the booster dose strategy in individuals previously vac-
cinated against HBV [50, 51]. The use of sHBsAg particles 
as carriers of small HCV epitopes inserted into the anti-
genic external hydrophilic loop was reported in several 
studies [23, 24, 52]. Another approach involved the design 
of chimeric HBV-HCV particles in which the N-terminal 
transmembrane domain (TMD) of the sHBsAg protein 
was replaced with the TMD of HCV full-length E1 or 
E2 proteins [19]. Those chimeric particles expressed in 
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CHO cells elicited strong antibody response against both 
HBsAg and HCV envelope proteins in immunized rab-
bits [53]. Moreover, the sera displayed cross-neutralizing 
activity against HCVpp and HCVcc, although the T-cell 
response of chimeric particles was not analyzed. Here, we 
tested the ability of Leishmania-derived particles to elicit 
a cellular response using an in vitro T cell activation assay. 
The strongest response occurred against sHBsAg peptide 
pools one and three. These results are in agreement with 
other reports suggesting that most T-cell immunodomi-
nant epitopes are located outside the “a”-determinant 
region [54, 55]. It also proves that the location of a foreign 
epitope does not interfere with cellular response against 
chimeric VLPs. Not surprisingly, no cellular response was 
detected when splenocytes were stimulated with 412–425 
synthetic peptide (the results not shown). The outcome 
supports the previous findings, namely that almost no cel-
lular epitopes were present on HCV envelope glycopro-
teins versus the core or NS proteins [5, 56]. Additionally, 
we observed a higher cellular response in mice immu-
nized with chimeric 412–425_sHBsAg particles than in 
those immunized with wild-type particles. An N-glycan 
structural analysis confirmed that L. tarentolae is able to 
produce mammalian-like, as well as mannose-terminated 
N-glycans [26]. Several reports show that mannosylation 
of particles enhances antigen uptake and processing by 
the antigen presenting cells [57–59]. Possibly, additional 
N-glycans present in 412–425_sHBsAg particles are 
mannose-terminated and may promote a stronger cellu-
lar response. Nevertheless, it should be emphasized that 
no significant differences in the humoral responses were 
observed.
The antibody response to mammalian and yeast-
derived sHBsAg is well documented [37, 60]. In this 
study, we proved strong immunogenicity of L. tarentolae-
derived particles, since the antibody titers in the sera of 
both analyzed mouse groups reached 5 ×  105 (Fig.  6a). 
The 412–425_sHBsAg sera were able to detect both 
synthetic peptide (Fig.  6c) and yeast-derived sHBsAg 
proteins (Fig.  6b). However, immune response against 
sHBsAg protein was weaker in the 412–425_sHBsAg 
group of mice than in the sHBsAg wild-type group. This 
is consistent with the previous findings which described 
lessening of the anti-sHBsAg immune response in ani-
mals immunized with chimeric particles versus those 
immunized with wild-type particles [24]. It has also been 
demonstrated that changes within external hydrophilic 
loop are strongly associated with the sHBsAg protein 
antigenicity [61]. Furthermore, our findings proved that 
412–425_sHBsAg sera were able to recognize not only 
the synthetic peptide, but also HCV E2 glycoprotein 
of most virus genotypes, which indicated presence of 
broadly cross-reactive antibodies (Fig. 6d).
There is abundant evidence clearly demonstrating the 
importance of the cross-neutralizing antibodies in spon-
taneous clearance of HCV infection. Promising results 
have been obtained for adenovirus-based vaccine proved 
to induce a broad, strong and long-lasting T-cell response 
in healthy humans [62]. Thus, the development of a pro-
phylactic vaccine can be achieved by combination of 
antigens which are able to elicit simultaneous T and B 
cell responses, both crucial for the successful protection 
against HCV [10, 36, 63].
Conclusions
Since HCV displays high genetic diversity, the ideal pro-
phylactic vaccine should elicit antibodies against the 
highly conserved viral regions. Our results indicate that 
chimeric sHBsAg VLPs carrying a highly conserved HCV 
epitope may elicit cross-reactive antibodies against HCV 
while preserving anti-sHBsAg “a”-determinant immu-
nogenicity. This approach, combined with a vaccine 
inducing a strong T-cell response against HCV, may be 
useful in developing a cost-effective bivalent prophylac-
tic vaccine against the two main hepatotropic human 
pathogens. Moreover, chimeric sHBsAg particles were 
successfully expressed in L. tarentolae system, which 
can be considered an alternative to mammalian cells for 




Figure  1 summarizes the construction of the 412–425_
sHBsAg chimeric gene used in this work. The region 
of HCV E2 glycoprotein, spanning the 412–425 resi-
dues (isolate H77c, GenBank accession no. AF011751) 
was inserted within HBV subtype adw2 sHBsAg amino 
acid positions 127P and 128A (GenBank accession no. 
AF397207.1). The construct was obtained by gene syn-
thesis using L. tarentolae-adapted codon (GeneArt—
Thermo Fisher Scientific). The gene coding for sHBsAg 
was synthetized as mentioned above. Synthetized genes 
were ligated into BglII—NotI restriction sites in the 
pLEXSY_I-blecherry3 vector (Jena Bioscience). For HCV 
E2 glycoprotein expression in human epithelial kidney 
(HEK) 293 cells, we used plasmids coding for full-length 
E1E2 derived from HCV genotypes: 1a (isolate H77.20); 
1b (UKN1B.12.6); 2a (UKN2A.2.4); 3a (UKN3.1.9); 4 
(UKN4.21.16); 5 (UKN5.14.4); and 6 (UKN6.5.8) – kindly 
provided by J. Ball.
Leishmania tarentolae cultivation and protein expression
HBV small surface antigen and 412–425_sHBsAg pro-
teins were expressed using the inducible LEXSY expres-
sion system according to the manufacturer’s instructions 
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(Jena Bioscience). Briefly, the plasmids were transfected 
into L. tarentolae cells by electroporation. Transfected 
cells were selected with bleomycin (100  µg/mL) in sus-
pension culture. Subsequently, recombinant cell lines 
were cultivated in 25 cm2 tissue culture flasks filled with 
10 mL of selective medium supplemented with hemin at 
26 °C and kept away from light. The T7 promoter driven 
transcription was induced by adding tetracycline to the 
final concentration of 15  µg/mL. Cells were grown in 
500 mL shake flasks for 72 h, at 26 °C, in agitated culture 
to the final optical density of 4–5 at 600 nm (OD600).
Indirect immunofluorescence
For immunofluorescence labeling, tetracycline-induced 
L. tarentolae cells were washed with PBS and fixed in 
4  % paraformaldehyde for 30  min at RT. Lysine-coated 
glass coverslips were covered with fixed cell suspension 
and left to dry at RT. Next, the cells were permeabilized 
with 0.2 % Triton X-100 in PBS for 10 min at RT. Subse-
quently, the coverslips were incubated with primary rab-
bit anti-HBsAg (Abcam) and mouse anti-E2 AP33 (kindly 
provided by A. Patel) antibodies diluted to 1:1000 in PBS-
BSA buffer [0.5  % (w/v) BSA] for 1  h at RT. The cover-
slips were then washed with PBS and incubated with 
Alexa Fluor 633-labeled goat anti-mouse and Alexa Fluor 
488-labeled goat anti-rabbit secondary antibodies (1:1000 
in PBS-BSA) for 1 h at RT. After washing, the coverslips 
were mounted onto microscope slides with ProLong 
Gold antifade reagent.
SDS‑PAGE and western blot
Analysis of the particle expression was carried out by 
SDS-PAGE using 4–12 % gradient Bis–Tris gels in MES 
SDS running buffer. After electrophoresis, proteins were 
transferred onto PVDF membrane using electroblotting, 
and subsequently the membranes were blocked over-
night at 4 °C with 3 % nonfat milk in TBST [TBS buffer, 
0.1  % (v/v) Tween-20]. Following blocking, membranes 
were incubated for 1  h at RT with primary anti-HBsAg 
antibodies diluted in TBST, washed with TBST, and then 
incubated with goat anti-rabbit secondary AP—conju-
gated antibodies (Santa Cruz Biotechnology). The results 
were developed using the BCIP/NBT substrate.
For testing serum cross-reactivity, HEK 293 cells were 
transfected with plasmids expressing glycoproteins E1E2 
derived from different HCV genotypes. 72 h after trans-
fection, cells were washed with PBS buffer and lysed in 
lysis buffer (PBS buffer, 1 % Triton X-100). The clarified 
cell lysates were separated using SDS-PAGE and trans-
ferred onto PVDF membrane as described above. Fol-
lowing the blocking, the membranes were incubated for 
1 h at RT with a mixture of pooled 412–425_sHBsAg sera 
diluted 1:500, washed with TBST and then incubated 
with goat anti-mouse secondary HRP—conjugated anti-
bodies (Santa Cruz Biotechnology).
PNGase F treatment
412–425_sHBsAg and sHBsAg cell lysates were boiled for 
10  min in denaturing buffer (0.5  % SDS, 40  mM DTT). 
The samples were divided into two equal portions and 
incubated for 16 h at 37  °C, with or without PNGase F, 
according to the manufacturer’s instructions (New Eng-
land Biolabs). The results were visualized with western 
blot using anti-HBsAg antibodies as described above.
Cell lysis and ultracentrifugation
Hundred milliliter of tetracycline-induced cell culture 
was centrifuged at 4  °C, 8000  rpm, for 15  min. The cell 
pellet was either stored at −20  °C until use or immedi-
ately resuspended in 10 mL of ice-cold lysis buffer [PBS 
buffer, 0.6  % (v/v) Tween-20]. Cells were sonicated and 
the suspension was clarified by centrifugation at 4  °C, 
8000  rpm, for 35  min.; the supernatant was left for 
16–24 h at RT for particle formation. Subsequently, the 
lysate was layered on an OptiPrep (Sigma-Aldrich) gra-
dient formed in ultra-clear tubes [2  mL of 30  % (v/v) 
OptiPrep, 2 mL 24 % (v/v) OptiPrep, 1.5 mL 18 % (v/v) 
OptiPrep, 1.5  mL 12  % (v/v) OptiPrep, and 1.5  mL 6  % 
(v/v) OptiPrep in ultra-clear water] and ultracentrifuged 
at 27,000  rpm for 16  h at 4  °C. Then, 500 µL fractions 
were harvested and analyzed by western blot using anti-
HBsAg rabbit polyclonal antibodies (Abcam). Purity of 
the fractions was analyzed by SDS-PAGE with Coomas-
sie R-250 staining. sHBsAg positive fractions of the high-
est purity were pooled, and OptiPrep buffer was replaced 
with PBS using Amicon Ultra 100  K centrifugal units 
(Merck Millipore). The thus prepared samples were used 
for further analysis.
Cell lysate ELISA
ELISA 96-well plates were left for coating with cell 
lysates diluted in PBS for 16 h at 4 °C. Each well was then 
blocked with 3 % (w/v) BSA in PBST [PBS buffer, 0.05 % 
(v/v) Tween-20] for 2 h at RT. Primary mouse monoclo-
nal AP33 and rabbit polyclonal anti-HBsAg (Acris Anti-
bodies) were diluted in PBST with 0.3 % (w/v) BSA and 
added to the wells. After the washing, primary antibod-
ies were detected with the goat anti-mouse or goat anti-
rabbit secondary HRP-conjugated antibodies (Santa Cruz 
Biotechnology). The reaction with TMB substrate was 
stopped with 0.5 M H2SO4 and signal intensity at 450 nm 
was measured using plate reader (TECAN).
Immunization protocol
Groups of 6 BALB/c female mice, 6–8  weeks of age, 
were immunized subcutaneously with squalene-based 
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oil-in-water nanoemulsion adjuvant (Addavax, Invivo-
Gen). The mice were immunized with 15 µg of protein on 
day 0, and with 10 µg on days: 14 and 28. The mice used 
as negative controls were immunized with PBS-adjuvant 
mixture alone. All experiments on animals were conducted 
by an accredited company (Tri-City Academic Laboratory 
Animal Centre, Medical University of Gdańsk), in accord-
ance with the current guidelines for animal experimenta-
tion. The protocols were approved by the Committee on 
the Ethics of Animal Experiments of the Medical Univer-
sity of Gdańsk (Permit Number: 46/2012). All surgery was 
performed under isoflurane anesthesia, and all efforts were 
made to minimize suffering.
Analysis of antibody response
Mouse sera were collected on day 42 and pooled into 
two groups. Antibody response was measured by direct 
solid-phase ELISA using immunogens 10  µg/mL, 412–
425 synthetic peptide (QLINTNGSWHINST) 20 µg/mL 
(JPT-Innovative Peptide Solutions), commercial vaccine 
against HBV 5  µg/mL (Engerix-B, GlaxoSmithKline) or 
yeast-derived HBsAg protein 5  µg/mL (Acris Antibod-
ies). Plates were blocked for 2  h with 3  % (w/v) BSA in 
PBST. Following the blocking and washing, serial diluted 
mouse sera were added to the wells and incubated for 1 h 
at RT. Diluted primary mouse AP33 mAb were used as 
reference. Secondary goat anti-mouse or goat anti-rabbit 
Abs were used for detection.
Statistical analysis
Statistical analyses were performed using the SigmaPlot 
12.0 software (SYSTAT Software).
ELISPOT assay
T-cell response was analyzed by ELISPOT assay for 
detection of IFN-γ according to the manufacturer’s 
instructions (BD Biosciences). Briefly, ELISPOT 96-well 
plates were coated with purified anti-mouse IFN-γ anti-
body and blocked using RPMI Medium 1640 (Thermo 
Fisher Scientific) supplemented with 10  % fetal bovine 
serum, 100  μg/mL penicillin, and 2  mM  l-glutamine. 
Splenocytes were isolated from the mice 42  days after 
immunization by passage through 70  μm strainers fol-
lowed by treatment with ACK lysing buffer (Thermo 
Fisher Scientific). After washing, splenocytes were 
seeded at 5 × 105 cells/well and stimulated overnight at 
37 °C with overlapping peptides (JPT-Innovative Peptide 
Solutions) pooled into 3 groups spanning the sHBsAg 
amino acid sequence at the concentration of 20  μg/mL. 
Concanavalin A was used as positive control. The mean 
number of spots from duplicate wells were calculated for 
each animal and adjusted to represent the mean number 
of spots per 106 splenocytes.
Electron microscopy and immunogold labeling
For visualization of the particles, the Optiprep gradient 
fractions were diluted 1:5 in PBS and deposited on form-
var-carbon coated 200 mesh nickel grids. Negative stain-
ing was performed using 2  % uranyl acetate. Following 
the staining, samples were analyzed using transmission 
electron microscope (University of Gdańsk, Poland). For 
immunogold labeling, grid-deposited 412–425_sHBsAg 
particles were fixed using 0.1  % (v/v) glutaraldehyde in 
4  % paraformaldehyde. Next, the grids were layered on 
top of AP33 antibodies diluted 1:20 in incubation buffer 
[PBS buffer, 0.1 % (v/v) BSA-c], and incubated at 4 °C for 
16 h. After incubation with primary antibodies, the grids 
were washed six times using incubation buffer for 5 min 
at RT. Labeling was performed with goat anti-mouse IgG 
conjugated with 6  nm gold particles (Aurion), diluted 
1:40 in incubation buffer and left for 1 h at RT. After the 
washing step, the grids were stained with uranyl acetate, 
dried and analyzed using transmission electron micro-
scope JEM 1200 EX (JEOL Co., Japan) at the Nencki 
Institute (Warszawa, Poland).
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